Figure 4.
NAC inhibits thrombin-induced PLA formation in JAK2V617Fknockin mice. (A) Representative gating strategy to measure circulating or thrombin-stimulated PLAs (based on CD45+/CD41+ double-positive events). PNAs are defined as CD45+/CD11b+/CD66b+ (for human) or Ly6G+ (for mice)/CD41+ events. (B) Bright-field image of unstimulated murine blood smear stained with Wright Giemsa. (C) Bright-field image of PLA (denoted by red arrowhead) from murine blood stimulated with 2 U thrombin. Original magnification ×60; scale bars represent 20 μm. (D-E) Quantification of PLAs (D) or PNAs (E) in WT or JAK2V617F knockin mice with or without NAC treatment. *P < .05, **P < .01, 2-way ANOVA. (F-G) Circulating PLAs (F) or PNAs (G) in fresh human blood from patients with PV and healthy donors. Each data point represents an individual. Error bars represent SEM. Shown are representative data from 3 biological replicates. SSC, side scatter.

NAC inhibits thrombin-induced PLA formation in JAK2V617Fknockin mice. (A) Representative gating strategy to measure circulating or thrombin-stimulated PLAs (based on CD45+/CD41+ double-positive events). PNAs are defined as CD45+/CD11b+/CD66b+ (for human) or Ly6G+ (for mice)/CD41+ events. (B) Bright-field image of unstimulated murine blood smear stained with Wright Giemsa. (C) Bright-field image of PLA (denoted by red arrowhead) from murine blood stimulated with 2 U thrombin. Original magnification ×60; scale bars represent 20 μm. (D-E) Quantification of PLAs (D) or PNAs (E) in WT or JAK2V617F knockin mice with or without NAC treatment. *P < .05, **P < .01, 2-way ANOVA. (F-G) Circulating PLAs (F) or PNAs (G) in fresh human blood from patients with PV and healthy donors. Each data point represents an individual. Error bars represent SEM. Shown are representative data from 3 biological replicates. SSC, side scatter.

Close Modal

or Create an Account

Close Modal
Close Modal